Evidence map›Paper›PMID 38822300›Full record

Trial reportBMC public health2024

The impact of intimate partner violence on PrEP adherence among U.S. Cisgender women at risk for HIV.

Katherine M Anderson, Jill Blumenthal, Sonia Jain, Xiaoying Sun, K Rivet Amico, Raphael Landovitz, Christine M Zachek, Sheldon Morris, David J Moore, Jamila K Stockman

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02584140 (Multimodal Interventions to Improve Adherence to Oral Tenofovir/Emtricitabine as Pre-Exposure Prophylaxis in Women in Southern California), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02584140 phase4completednot on this map

Multimodal Interventions to Improve Adherence to Oral Tenofovir/Emtricitabine as Pre-Exposure Prophylaxis in Women in Southern California

TypeinterventionalSponsorUniversity of California, Los AngelesRan2016 to 2019Enrolled136ConditionsHIV PreventionArmsText Messaging, Adherence Counseling, Daily Oral PrEP
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katherine M AndersonDivision of Infectious Diseases and Global Public Health, Department of Medicine, School of Medicine, University of California, 9500 Gilman Dr., La Jolla, San Diego, CA, 92093-0507, USA. K4anderson@health.ucsd.edu.
Jill BlumenthalDivision of Infectious Diseases and Global Public Health, Department of Medicine, School of Medicine, University of California, 9500 Gilman Dr., La Jolla, San Diego, CA, 92093-0507, USA.
Sonia JainBiostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, 9500 Gilman Dr., La Jolla, San Diego, CA, 92093-0725, USA.
Xiaoying SunBiostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, 9500 Gilman Dr., La Jolla, San Diego, CA, 92093-0725, USA.
K Rivet AmicoDepartment of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, 48109, USA.
Raphael LandovitzDavid Geffen School of Medicine, UCLA Center for Clinical AIDS Research & Education, University of California Los Angeles, Los Angeles, CA, 90024, USA.
Christine M ZachekDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California San Diego Health, 9300 Campus Point Drive, La Jolla, San Diego, CA, 92037, USA.
Sheldon MorrisDivision of Infectious Diseases and Global Public Health, Department of Medicine, School of Medicine, University of California, 9500 Gilman Dr., La Jolla, San Diego, CA, 92093-0507, USA.
David J MooreDepartment of Psychiatry, University of California San Diego, San Diego, CA, 92103, USA.
Jamila K StockmanDivision of Infectious Diseases and Global Public Health, Department of Medicine, School of Medicine, University of California, 9500 Gilman Dr., La Jolla, San Diego, CA, 92093-0507, USA.

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
California HIV/AIDS Research Program EI11-SD-005BCenter for AIDS Research, University of California, San Diego P30AI036214NIAID NIH HHS P30 AI036214NIH HHS KL2TR001444NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

backgroundCisgender women account for 1 in 5 new HIV infections in the United States, yet remain under-engaged in HIV prevention. Women experiencing violence face risk for HIV due to biological and behavioral mechanisms, and barriers to prevention, such as challenges to Pre-Exposure Prophylaxis for HIV Prevention (PrEP) adherence. In this analysis, we aim to characterize intimate partner violence (IPV) among cisgender heterosexual women enrolled in a PrEP demonstration project and assess the associations with PrEP adherence.

methodsAdherence Enhancement Guided by Individualized Texting and Drug Levels (AEGiS) was a 48-week single-arm open-label study of PrEP adherence in HIV-negative cisgender women in Southern California (N = 130) offered daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). From 6/2016 to 10/2018, women completed a survey reporting HIV risk behavior and experiences of any IPV (past 90-days) and IPV sub-types (past-year, lifetime) and biological testing for HIV/STIs at baseline, and concentrations of tenofovir-diphosphate (TFV-DP) in dried blood spots at weeks 4, 12, 24, 36, and 48. Outcomes were TFV-DP concentrations consistent with ≥ 4 or ≥ 6 doses/week at one or multiple visits. Multivariable logistic regression models were conducted to examine associations.

resultsPast-90-day IPV was reported by 34.4% of participants, and past-year and lifetime subtypes reported by 11.5-41.5%, and 21.5-52.3%, respectively. Women who engaged in sex work and Black women were significantly more likely to report IPV than others. Lifetime physical IPV was negatively associated with adherence at ≥ 4 doses/week at ≥ 3 of 5 visits, while other relationships with any IPV and IPV sub-types were variable.

conclusionIPV is an indication for PrEP and important indicator of HIV risk; our findings suggest that physical IPV may also negatively impact long-term PrEP adherence. CLINICAL TRIALS REGISTRATION: NCT02584140 (ClinicalTrials.gov), registered 15/10/2015.

Indexed as

Drug MonitoringHIV InfectionsIntimate Partner ViolencePre-Exposure ProphylaxisAdolescentAdultAnti-HIV AgentsCaliforniaFemaleHumansMiddle AgedTenofovirUnited StatesYoung AdultAnti-HIV AgentsTenofovirAdherenceIntimate Partner violencePre-exposure Prophylaxis for HIV PreventionViolence

Identifiers

PMID38822300
PMCPMC11140862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.